Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease

Background: Heart failure (HF) is the leading cause of hospitalizations and death in patients with adult congenital heart disease (ACHD). Sacubitril/valsartan is a new agent in the treatment of HF, but its effects have not been assessed in ACHD. Methods: We retrospectively studied all 15 patients wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	World journal for pediatric & congenital heart surgery 2019-05, Vol.10 (3), p.292-295
Hauptverfasser:	Lluri, Gentian, Lin, Jeannette, Reardon, Leigh, Miner, Pamela, Whalen, Katrina, Aboulhosn, Jamil
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Aminobutyrates - therapeutic use Angiotensin II Type 1 Receptor Blockers - therapeutic use Angiotensin Receptor Antagonists - therapeutic use Drug Combinations Female Follow-Up Studies Heart Defects, Congenital - complications Heart Defects, Congenital - drug therapy Heart Failure - diagnosis Heart Failure - drug therapy Heart Failure - etiology Humans Male Middle Aged Neprilysin Retrospective Studies Stroke Volume - physiology Tetrazoles - therapeutic use Time Factors Treatment Outcome Valsartan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!